(Correction: Corrects typo in NIAID in the headline.)
Tuesday, Nabi Biopharmaceuticals (NABI) announced that it has entered into collaboration with the National Institute of Allergy and Infectious Diseases, or NIAID, to advance its PentaStaph vaccine candidate for the prevention and treatment of S.aureus infections in the community and hospital settings.
The PentaStaph or Pentavalent S. aureus Vaccine is a five-component vaccine. Three of the antigen components induce antibodies that target S. aureus capsular polysaccharides Types 5, 8 and the cell wall antigen Type 336, enhancing the immune systems' ability to clear bacteria from the host.
The Rockville, Maryland-based company's collaboration with the NIAID is expected to focus on conducting pre-clinical toxicology evaluations of two new S. aureus antigens as components of the first-in-class, multivalent vaccine, targeting S. aureus infections.
The NIAID will fund the pre-clinical toxicology evaluations of the vaccine components manufactured and provided by Nabi. The two novel antigens are designed to protect against two of the most virulent and debilitating toxins produced by the bacteria: Panton-Valentine Leukocidin, found predominantly in community-acquired methicillin-resistant S. aureus and alpha toxin, produced by almost all S. aureus isolates.
Raafat Fahim, President and Chief Executive Officer, Nabi Biopharma said, "In addition to the financial support, the collaboration with NIAID underscores the acute need for an S. aureus vaccine and enables testing of the PentaStaph multi-targeted approach for the prevention of S. aureus infections. We believe that PentaStaph has the potential to provide the widest spectrum of protection against the most clinically significant S. aureus infections known today."
Pre-clinical toxicology testing of these components will help enable the initiation of Phase-1 clinical trials for these new antigens in early 2009, which is one of the Company's three development milestones for 2008.
After closing lower in the four previous sessions, shares of NABI are currently unchanged at $5.60 on a volume of 36,000 shares.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.